New data published in the New England Journal of Medicine (NEJM) and featured at the European Society for Medical Oncology (ESMO) Congress 2021 highlights a promising new treatment for individuals with HER2-mutant non-small cell lung cancer (NSCLC).
Newswise: Latest News
International Clinical Trial Delivers Promising Results of HER2-Targeted Therapy for Non-Small Cell Lung Cancer
September 18, 2021By
